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Abstract: Malignant pleural mesothelioma (MPM) is difficult to
measure radiographically due to the nonradial and variable pattern
of growth and response to therapy. Inaccurate and inconsistent
tumor measurements often compromise results from clinical trials
that are dependent on identifying response rate and progression-free
survival. In this article, we sought to provide a practical guide
through the Southwest Oncology Group on how to measure MPM
by the updated RECIST version 1.1 and by modified RECIST. We
hope that these steps will provide a simple means by which com-
puted tomography measurements can be consistently performed,
minimizing intra- and interobserver variability. With this consis-
tency, we may be able to better estimate the prognosis and response
to therapy. With greater utilization, we will be able to better
understand the biology of MPM.
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Radiographically, malignant pleural mesothelioma (MPM)is difficult to measure given the nonradial and inconsis-
tent pattern of growth and response to treatment. Clinical
trials that use primary endpoints dependent on radiographic
imaging, such as progression-free survival and response rate,
may be compromised by inaccuracy of tumor measurements,
inconsistency in measurement technique between clinicians,
and a lack of experience in measuring pleural tumors, given
the relative rarity of MPM. Currently, the measurement
methods for MPM are either the RECIST1,2 or the newer
modified RECIST criteria.3 Modified RECIST was developed
based on speculation that RECIST did not address the unique
shape of mesothelioma tumors with the pleural rind and thus
led to inaccurate measurements.4–6
The summarized definitions of the two methods are as
follows:
RECIST1,2: Ameasurable target lesion must be 2 cm or more
when using cross-sectional imaging with a non-spiral
computed tomopgraphy (CT) scan or MRI. If using a
spiral CT scan, the measurements must be greater than 1
cm. Measure the long axis of the tumor to achieve the
longest uni-dimensional measurement. With the updated
RECIST criteria (version 1.1),2 the number of target
lesions required to assess clinical response has been
reduced to a maximum of five measurements. Each
involved organ site that has a measurable target lesion
should be represented in this measurement. However, only 2
maximum measurements per organ are allowed. Therefore,
only two pleural tumor uni-dimensional measurements for
mesothelioma are required.
Tip for RECIST v1.1 reporting on pleural rind-like masses:
Measure the longest diameter of the tumor along the chest
wall.
Modified RECIST3: Uni-dimensional measurements of tumor
thickness perpendicular to the chest wall or mediastinum
should be performed, measured in 2 sites at 3 different levels
on CT scan. Transverse cuts used for measurement must be at
least 1 cm apart, and related to anatomical landmarks in the
thorax, preferably above the level of division of the main
bronchi. At reassessment, pleural thickness must be mea-
sured at the same position and level. Nodal, subcutane-
ous, and other bi-dimensionally measurable lesions are
measured uni-dimensionally as per the RECIST2 crite-
ria. Uni-dimensional measurements are added to pro-
duce the total tumor measurement.
The sum of 6 pleural thickness measurements  one
univariate diameter.
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Although both methods define distinct rules of MPM
measurements, these measurement techniques have been applied
in a highly variable fashion by medical oncologists and radiol-
ogists, and obtaining accurate tumor measurements remains a
dilemma for mesothelioma multicenter clinical trials. Ulti-
mately, the future of mesothelioma clinical research may be
dependent on volumetric measurements or fluorodeoxyglucose-
positron emission tomography CT scans; these systems provide
numerical values that should minimize interobserver variability
and simplify the technique. To date, these volumetric methods
are not validated and require further study before their imple-
mentation in large-scale clinical trials.7–9 Educating clinicians in
the proper application of the RECIST and modified RECIST
systems and standardization of the manner in which the mea-
surements are made is essential. There is no practical guideline
to assist in the radiological assessment of pleural mesothelioma.
We will attempt to provide detailed practical instructions on how
to measure MPM by the updated RECIST version 1.1 and
modified RECIST guidelines detailed earlier in the text.
HOW TO MAKE MEASUREMENTS OF MPM BY
MODIFIED RECIST
Tips
Y Larger lesions are easier and more accurate to measure.
Choose the larger or thickest of the pleural disease to
measure. Magnifying the image may enable an easier
measurement.
Y The short-axis diameter is defined as the shortestpathway
from the tip of the tumor to the chest wall (Figure 1).
Y Ensure that differentiation of normal chest wall
from tumor is easy at the point of measurement
(Figure 2).
FIGURE 1. Example of well formulated and erroneous measurements using modified RECIST. A, Good measurement: the
pleural disease has a short-axis measurement of 3.2 cm. The short axis is always measured perpendicular, or 90 degrees, to
the chest wall or mediastinum and is the measurement between the point the pleural disease touches the chest wall/mediasti-
num and the point where the pleural disease touches normal lung. B, Malpositioned caliper: although this measurement takes
a short path to the chest wall, perpendicular to the chest wall, it does not pass entirely through the tumor before meeting the
chest wall and is therefore an erroneous measurement. C, Malpositioned caliper: although the measurement goes through
tumor tissue, the path is not the shortest going to the chest wall, i.e., perpendicular. It forms an acute angle to the point
where the pleural disease interfaces with the mediastinum and is therefore incorrect.
FIGURE 2. Examples of pleural disease interfaces with the chest wall or mediastinum. A, Example of a good interface to measure.
There is a clear, well-marginated differentiation between the pleural tumor and the normal mediastinal fat (arrow). B, Example of a
poor interface to measure. The border of the pleural tumor compared with normal tissues is not clear or distinct (circle). C, If choos-
ing to measure the interface seen in B, measurements may erroneously underestimate tumor burden. D, If choosing to measure the
interface seen in B, measurements may erroneously overestimate tumor burden.
Journal of Thoracic Oncology • Volume 6, Number 3, March 2011 A Practical Guide of the Southwest Oncology Group
Copyright © 2011 by the International Association for the Study of Lung Cancer 599
1. To ensure accuracy, all measurements must be per-
formed electronically in the same window setting on
consecutive studies. We recommend using the “soft
tissue” setting (not lung windows), as it enables accu-
rate pleural mass measurements with the electronic
calipers and avoids the incorporation of chest wall or
mediastinal fat within the calculations, which are not as
easily identified when using lung windows.
2. CT scan slices up to 5 mm can be used, but for greater
accuracy, thinner slices such as 2.5 mm are preferable.
Ideally, all subsequent CT scans should use the same
slice thickness.
3. To limit interobserver variability in measuring tumor re-
sponse, it is preferred that the same clinician measure the
tumors at baseline and on all subsequent CT scans.
4. The pleural disease to be measured should have a
short-axis diameter of at least 1 cm, as lesions less than
1 cm are considered nonmeasurable.
5. To obtain the short axis of the disease, with electronic
calipers, measure the distance between the point where the
tumor abuts the chest or the mediastinal border and the
point where the pleural disease touches normal lung (Fig-
ure 1A). The shortest route possible is the one perpendic-
ular to the chest wall/mediastinum.
6. Avoid measuring regions where tumor infiltration ob-
scures the interface of tumor to normal tissue. A good
interface for measurement is usually one where the tumor
abuts fat or an intact rib/vertebral body, as the density of
the pleural tumor differs significantly from bone or fat and
the difference can be easily observed. Avoid choosing an
interface of tumor with muscle, as muscle and tumor have
similar CT densities and are often difficult to distinguish
when they abut one another (Figure 1).
7. Following the instructions in 5, choose three different
axial slices, preferably above the level of the main
bronchi and record two measurements per slice, thus
resulting in six separate measurements (Figure 3).
8. If any additional nodal, subcutaneous or other bidi-
mensionally measureable lesions are available, they
should undergo unidimensional measurements by RE-
CIST version 1.1 and be added to the total obtained
from 7.
FIGURE 3. Comparison of tumor
measurements using the updated
RECIST criteria version 1.1 (i, iii, v) and
the modified RECIST criteria (ii, iv, vi).
*Although additional measurements
were made of the pleural tumor in the
patient example (see Figure 3i.); by
RECIST version 1.1, only the 2 longest
measurements of the pleural tumor are
used in calculating the total RECIST v.
1.1 measurement. For the example,
this patient had pleural tumor mea-
surements of 5.3 cm, 6.1 cm, 10.9 cm,
and 8.2 cm. The 2 longest measure-
ments (10.9 cm, 8.2 cm) were chosen
to be added together for the total
RECIST v1.1 measurement (19.1 cm).
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Tips on Lymph Node Measurements
Lymph nodes are considered as a separate organ to
measure, and up to two lymph nodes can be measured per
patient by RECIST version 1.1.2 For unidimensional
lymph node measurements,10 use the short axis of the
lymph node at baseline and then at every follow-up scan
(Figure 4). To be considered as pathologically enlarged
and measurable at baseline, the lymph node short-axis
diameter should be 15 mm.
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FIGURE 4. Lymph node measurements. Schematic representation of a horizontally oriented (A) or vertically oriented (B) lymph node
and an enlarged subcarinal lymph node on contrast enhanced chest computed tomography (CT) at the level of the right pulmonary ar-
tery (C). Arrow denotes the short axis of the lymph nodes in A and B, and in the caliper measurements of the short axis of the 33.4 mm
subcarinal lymph node seen in C. As an example, the measurements of the lymph node in C would be added to the pleural measure-
ments obtained in Figure 3. RECIST method v1.1: total measurement  pleura (10.9  8.2  19.1 cm)  lymph node (3.3 cm)  22.4
cm. Modified RECIST: total measurement  pleura (3.2  3.3  2.2  3.8  2.5  3.8  18.8 cm)  lymph node (3.3 cm)  22.1 cm.
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